BRIEF published on 05/22/2025 at 07:05, 10 months 4 days ago Relief Therapeutics Secures FDA Rare Pediatric Disease Designation for RLF-TD011 FDA Relief Therapeutics RLF-TD011 Epidermolysis Bullosa Rare Pediatric Disease
PRESS RELEASE published on 05/22/2025 at 07:00, 10 months 4 days ago Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011 Relief Therapeutics granted FDA Rare Pediatric Disease Designation for RLF-TD011 in treating epidermolysis bullosa, a rare genetic skin disorder. Potent antimicrobial & anti-inflammatory activity shown FDA Relief Therapeutics RLF-TD011 Epidermolysis Bullosa Rare Pediatric Disease Designation
BRIEF published on 05/15/2025 at 07:05, 10 months 11 days ago Relief Therapeutics Announces 2025 AGM Agenda Annual General Meeting Financial Statements Shareholder Voting Board Re-election Compensation Approval
PRESS RELEASE published on 05/15/2025 at 07:00, 10 months 11 days ago Relief Therapeutics Publishes 2025 Annual General Meeting Agenda Relief Therapeutics announces agenda for its 2025 Annual General Meeting featuring key resolutions and re-elections. Meeting scheduled for June 12 in Geneva, Switzerland Shareholders Switzerland Relief Therapeutics Agenda 2025 Annual General Meeting
BRIEF published on 04/10/2025 at 07:05, 11 months 16 days ago Relief Therapeutics Announces 2024 Financial Results and Strategic Progress Biopharmaceutical Relief Therapeutics Rare Diseases 2024 Financial Results Pipeline Progress
PRESS RELEASE published on 04/10/2025 at 07:00, 11 months 16 days ago Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update Relief Therapeutics reports 2024 financial results and provides a corporate update, emphasizing operational achievements, pipeline momentum, and strengthened financial position Biopharmaceutical Corporate Update Relief Therapeutics Rare Diseases 2024 Financial Results
BRIEF published on 03/06/2025 at 07:05, 1 year ago Relief Therapeutics Ends Merger Discussions with Renexxion Shareholder Value Relief Therapeutics Strategic Objectives Renexxion Merger Termination
PRESS RELEASE published on 03/06/2025 at 07:00, 1 year ago Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion Relief Therapeutics terminates merger discussions with Renexxion after failing to meet key conditions. Company remains well-positioned with robust pipeline and cash reserves Relief Therapeutics Cash Reserves Therapeutic Pipeline Renexxion Merger Discussions
BRIEF published on 02/11/2025 at 07:05, 1 year 1 month ago European Patent Office Grants Relief Therapeutics Patent for RLF-TD011 Biopharmaceuticals Relief Therapeutics RLF-TD011 European Patent Epidermolysis Bullosa
PRESS RELEASE published on 02/11/2025 at 07:00, 1 year 1 month ago Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011 Relief Therapeutics obtains European Patent Office grant for RLF-TD011, securing patent protection for epidermolysis bullosa treatment. Company advances wound care solution Relief Therapeutics European Patent Office Epidermolysis Bullosa Wound Treatment RLD-TD011
Published on 03/26/2026 at 16:20, 1 hour 44 minutes ago ACCESS Newswire Upgrades the ACCESS Platform to Include Social Monitoring to Track Brand Conversations Across Major Social Platforms
Published on 03/26/2026 at 13:00, 5 hours 4 minutes ago Prospect Ridge Strengthens Technical Team with Appointment of Phil Smerchanski as Senior Technical Advisor
Published on 03/26/2026 at 13:00, 5 hours 4 minutes ago GameSquare's Stream Hatchet Launches Creator Communities to Manage the Full Creator Marketing Lifecycle
Published on 03/26/2026 at 12:59, 5 hours 5 minutes ago Adcore Concludes Fiscal Year 2025 With Strong Q4 Performance
Published on 03/26/2026 at 17:51, 12 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/26/2026 at 17:45, 19 minutes ago CTS EVENTIM exceeds EUR 3 billion in revenue for the first time, sustaining profitable growth
Published on 03/26/2026 at 17:20, 43 minutes ago EQS-Adhoc: Leifheit Aktiengesellschaft: Board of Management and Supervisory Board propose to the Annual General Meeting a capital increase from the company’s own funds, followed by an ordinary capital reduction
Published on 03/26/2026 at 17:19, 44 minutes ago Haier Smart Home Reports Full-Year 2025 Results: Global Revenue Surpasses RMB 300 Billion for the First Time; Net Profit Reaches a Record Highs
Published on 03/26/2026 at 07:30, 10 hours 34 minutes ago BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY
Published on 03/25/2026 at 18:31, 23 hours 32 minutes ago Strong investment performance and active roll-out of our strategy
